Source:http://linkedlifedata.com/resource/pubmed/id/15468046
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4 Suppl 5
|
| pubmed:dateCreated |
2004-10-6
|
| pubmed:abstractText |
For patients with type 1 Gaucher disease, challenges to patient care posed by clinical heterogeneity, variable progression rates, and potential permanent disability that can result from untreated or suboptimally treated hematologic, skeletal, and visceral organ involvement dictate a need for comprehensive, serial monitoring. An updated consensus on minimum recommendations for effective monitoring of all adult patients with type 1 Gaucher disease has been developed by the International Collaborative Gaucher Group (ICGG) Registry coordinators. These recommendations provide a schedule for comprehensive and reproducible evaluation and monitoring of all clinically relevant aspects of this disease. The initial assessment should include confirmation of deficiency of beta-glucocerebrosidase, genotyping, and a complete family medical history. Other assessments to be performed initially and at regular intervals include a complete physical examination, patient-reported quality of life using the SF-36 survey, and assessment of hematologic (hemoglobin and platelet count), visceral, and skeletal involvement, and biomarkers. Specific radiologic imaging techniques are recommended for evaluating visceral and skeletal pathology. All patients should undergo comprehensive regular assessment, the frequency of which depends on treatment status and whether therapeutic goals have been achieved. Additionally, reassessment should be performed whenever enzyme therapy dose is altered, or in case of significant clinical complication.
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
0037-1963
|
| pubmed:author |
pubmed-author:AggioMario CMC,
pubmed-author:AnderssonHans CHC,
pubmed-author:AndriaGenerosoG,
pubmed-author:CharrowJoelJ,
pubmed-author:ClarkeJoe T RJT,
pubmed-author:EriksonAndersA,
pubmed-author:GiraldoPilarP,
pubmed-author:GoldblattJackJ,
pubmed-author:HollakCarlaC,
pubmed-author:IdaHiroyukiH,
pubmed-author:International Collaborative Gaucher Group (ICGG),
pubmed-author:KaplanPaigeP,
pubmed-author:KolodnyEdwin HEH,
pubmed-author:MistryPramodP,
pubmed-author:PastoresGregory MGM,
pubmed-author:PiresRicardoR,
pubmed-author:Prakash-ChengAinuA,
pubmed-author:Prakesh-ChengAinuA,
pubmed-author:RosenbloomBarry EBE,
pubmed-author:ScottC RonaldCR,
pubmed-author:SobreiraElisaE,
pubmed-author:Tylki-Szyma?skaAnnaA,
pubmed-author:VellodiAshokA,
pubmed-author:WappnerRebecca SRS,
pubmed-author:WeinrebNeal JNJ,
pubmed-author:ZimranAriA,
pubmed-author:vom DahlStephanS
|
| pubmed:issnType |
Print
|
| pubmed:volume |
41
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
15-22
|
| pubmed:dateRevised |
2005-9-2
|
| pubmed:meshHeading |
pubmed-meshheading:15468046-Adult,
pubmed-meshheading:15468046-Biological Markers,
pubmed-meshheading:15468046-Cytogenetic Analysis,
pubmed-meshheading:15468046-Diagnostic Imaging,
pubmed-meshheading:15468046-Gaucher Disease,
pubmed-meshheading:15468046-Hematologic Tests,
pubmed-meshheading:15468046-Humans,
pubmed-meshheading:15468046-Registries
|
| pubmed:year |
2004
|
| pubmed:articleTitle |
Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients.
|
| pubmed:affiliation |
University Research Foundation for Lysosomal Storage Diseases, Department of Medicine, University Hospital, Tamarac, FL, USA.
|
| pubmed:publicationType |
Journal Article,
Guideline,
Practice Guideline
|